Taiwan Advance Bio-Pharmaceutical Inc. (TPEX:4186)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
7.20
-0.05 (-0.69%)
Sep 15, 2026, 1:20 PM CST

TPEX:4186 Financials Overview

Millions TWD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
348.54364.79354.17315.98318.24243.36
Revenue Growth
-4.45%3.00%12.09%-0.71%30.77%3.31%
Gross Profit
213.66234.07243.97198.46192.58124.79
Operating Income
26.7737.3944.844.277.61-102.79
Net Income
15.7628.0522.88-10.683.17-118.53
Earnings Per Share
0.170.310.25-0.120.04-1.32
EPS Growth
-44.05%24.00%----

Revenue by Segment

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Food Safety Business Division
41.4737.6430.6339.1951.8850.4
Inspection Business Division
106.3994.9282.6175.8977.9462.94
Precise Medical Division
135.82143.55146.06200.91188.42130.03
New Business Division
64.8688.6894.87---
Total
348.64364.79354.17315.98318.24243.36

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
157.98140.74106.32182.14158.56159.7
Total Debt
294.24264.12229.64307.24279.7248.97
Net Cash (Debt)
-136.26-123.38-123.32-125.11-121.15-89.27
Net Cash Growth
------
Net Cash Per Share
-1.51-1.37-1.37-1.39-1.35-0.99

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
54.5653.138.3312.61-20.59-48.08
Capital Expenditures
-34.54-33.36-3.96-11.94-7.28-15.19
Free Cash Flow
20.0219.774.370.67-27.87-63.28
Free Cash Flow Growth
1.26%352.74%554.72%---

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
61.30%64.17%68.88%62.80%60.51%51.28%
Operating Margin
7.68%10.25%12.66%1.35%2.39%-42.24%
Pretax Margin
4.27%7.44%6.38%-3.60%1.16%-47.03%
Profit Margin
4.52%7.69%6.46%-3.38%1.00%-48.70%
FCF Margin
5.74%5.42%1.23%0.21%-8.76%-26.00%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
52.7035.7861.97-502.52-
P/FCF Ratio
41.0950.76324.592226.39--
PS Ratio
2.362.754.004.705.016.88